标普和纳斯达克内在价值 联系我们

Heska Corporation HSKA NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
53/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$159.50
+32.9%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Heska Corporation (HSKA) .

本页证实的标准:

  • VALUE (90/100, 通过) — 分析师目标价暗示上行空间 (+32.9%).
  • 分析师共识目标价 $159.50 (+32.9% 上行空间) — 华尔街分析师认为存在显著上行潜力。

SharesGrow 综合评分: 53/100 其中 2/7 项标准通过。

SharesGrow 7-Criteria Score
53/100
SG Score
View full scorecard →
价值
90/100
Price-to-Earnings & upside
Proven by this page
未來
64/100
Analyst consensus
→ Forecast
过去
25/100
→ Income
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
~
护城河
59/100
→ Income
~
成长
58/100
→ Income
收入
10/100
→ Income

估值概览 — HSKA

估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率4.82
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.78
每股账面价值$0.00
每股营收$24.88
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$159.50 (+32.9%)

EPS:实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year EPS(稀释) 营收 净利润 净利润率
2013 $-0.21 $78.34M $-1.2M -1.5%
2014 $0.41 $89.84M $2.6M 2.9%
2015 $0.74 $104.6M $5.24M 5%
2016 $1.43 $130.08M $10.51M 8.1%
2017 $1.30 $129.34M $9.95M 7.7%
2018 $0.74 $127.45M $5.85M 4.6%
2019 $-0.15 $122.66M $-1.14M -0.9%
2020 $-1.62 $197.32M $-14.03M -7.1%
2021 $0.01 $253.74M $132K 0.1%
2022 $-1.78 $257.31M $-18.42M -7.2%
联系我们
🎓
SharesGrow 学院
学习如何计算内在价值,发现被低估的股票。
每周在线课程
给我们留言